

ARTICLE

Mutation analysis of candidate genes within the 2q33.3 linkage area for familial early-onset generalised osteoarthritis

Josine L Min¹, Ingrid Meulenbelt^{*,1}, Margreet Kloppenburg², Cornelia M van Duijn³ and P Eline Slagboom¹

¹Molecular Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands; ²Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands; ³Department of Epidemiology & Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands

In a genome-wide linkage scan of seven families with familial early-onset osteoarthritis (FOA), we mapped a FOA locus to a 5 cM region on chromosome 2q33.3–2q34 with a maximum LOD score of 6.05. To identify causal variants, 17 positional candidate genes and *FRZB* were sequenced for coding, splice sites, and 5' and 3' untranslated regions. The pathogenicity of possible disease-causing variants was evaluated using predicted effects on protein structure and function, splicing enhancers, degree of conservation and frequency in 790 unrelated subjects from the population-based Rotterdam study scored for the presence of radiographic signs of OA (ROA). Nine novel variants, identified in *NRP2*, *XM_371590*, *ADAM23*, *IDH1*, *PIP5K3* and *PTHR2*, cosegregated with FOA, of which two were promising. *IDH1* Y183C cosegregated in one family, involved a conserved amino-acid change and showed a damaging effect predicted by PolyPhen and SIFT. In the Rotterdam sample, carriers of *IDH1* Y183C (0.02) had an increased but insignificant risk for generalised ROA. The second variant, *NRP2* c.1938-21T>C cosegregated in three families. In the Rotterdam sample, carriers conferred an increased risk of 2.1 (95% confidence interval, 1.1–4.1, $P=0.032$) to have generalised ROA. Furthermore, two variants (*NRP2* c.1938–21T>C and *IDH1* c.933-28C>T) occurred together on the haplotypes segregating with FOA in two out seven families. This haplotype was rare in the Rotterdam sample (0.0013). Two promising variants in or near *NRP2* and *IDH1* may not be sufficient for the onset of FOA alone but might have a modulating role with FOA. Confirmation in other OA populations is required.

European Journal of Human Genetics (2007) 15, 791–799; doi:10.1038/sj.ejhg.5201829; published online 4 April 2007

Keywords: early-onset osteoarthritis; variants; mutation analysis; 2q33.3; *IDH1*; *NRP2*

Introduction

Osteoarthritis (OA) is the most common joint disease and is the leading cause of disability among the elderly. It is a degenerative disease of the joints characterized by cartilage

degeneration and subchondral bone remodelling. Clinically, OA manifests itself with pain, stiffness, disability and loss of joint function. Twin, sibling and segregation studies have highlighted substantial heritability for primary OA ranging between 39 and 80% depending on the sex and joint location.^{1,2} OA often arises as a complex trait, but rare familial forms with autosomal dominant transmission have been reported.^{3–5} The phenotype of these rare OA families resembles common OA at later ages in the population except for the early age of onset (20–50 years)

*Correspondence: Dr I Meulenbelt, Section Molecular Epidemiology (S-05-P), Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands. Tel: +31 71 5269734; Fax +31 71 5268280; E-mail: i.meulenbelt@lumc.nl
Received 11 October 2006; revised 1 March 2007; accepted 1 March 2007; published online 4 April 2007

and the progressive course of the disease. In familial forms of osteochondrodysplasia often displayed with secondary early-onset OA, mutations in several structural genes of the extracellular cartilage matrix (ECM) including *COL2A1*, *COL9A1*, and *COMP* have been identified.⁶ There is no convincing evidence yet that these genes are implicated in the susceptibility for primary early-onset OA occurring without dysplasia.^{4,6,7} Linkage and association studies on the basis of joint- or sex-specific OA definitions have yielded several loci associated with common OA susceptibility including *MATN3*,^{8,9} *FRZB*,^{10–12} *IL4R*,¹³ *ASPN*¹⁴ and *CALM1*.¹⁵

Previously, we mapped a locus for early-onset osteoarthritis (familial OA, FOA) in seven families to 2q33.3–2q34.¹⁶ The high LOD score in the early-onset OA families and absence of variants in the two most promising genes (*FZD5* and *PTHR2*) prompted us to perform an extended systemic mutation analysis of candidate genes in the 2q33.3–2q34 linkage area. Additionally, we screened for mutations in the *FRZB* gene, which is localised at 2q32, slightly outside our linkage region. In the present study, we report results of mutation screening of the entire coding region, splice sites, and 5' and 3' untranslated regions (UTR) of 17 positional candidate genes and the *FRZB* gene in affected family members with early-onset generalised OA.

Materials and methods

Families

Families containing patients that express primary generalised OA in each generation were collected from different parts of the Netherlands. Informed consent was obtained from all patients and the Medical Ethics Committee of the Leiden University Medical Centre approved the study. Proband was recognised through Rheumatology outpatient clinics. Family members were recruited via probands. Initially, we used questionnaires to select eligible families. For eligible families, complete medical history and available radiographs were obtained from Rheumatologists of almost all affected family members (81%). Radiographs were re-evaluated for signs of chondrodysplasia, spinal dysplasia and abnormal development or growth of the articular and growth-plate cartilages including epiphyses of the peripheral joints. As previously described in Meulenbelt *et al.*,⁵ these features were absent in all families. The presence of radiographic OA (ROA) was assessed according to Kellgren/Lawrence criteria¹⁷ by an experienced reader. Some individuals had marked Heberden's nodes and ankle OA. A selection of affected and unaffected individuals of family 1, 2, 4 and 7 were additionally visited for physical examination in order to prevent misclassification. The mean age of onset of OA in these patients was 33 years ranging between 20 and 50 years. The phenotype within these families is characterised by distinct progressive OA in the absence of mild or severe

chondrodysplasia, however, with symptoms and ROA at multiple joint sites simultaneously including involvement of the hands with noduli, knees, hips, ankle and spine. Individuals with clinical and radiographic evidence of OA in two or more joint sites before the age of 50 years were considered affected. Extensive description of the phenotype in family 1, which is representative for the phenotypes also of the other extended families included, is described elsewhere.⁵ All clinical diagnostic decisions were made independent to genetic linkage analysis and homogeneity of the phenotype between different families was checked.

The Rotterdam sample

The Rotterdam study, which comprises 7983 Caucasian participants is a prospective, population-based cohort study of the determinants and prognosis of chronic diseases in the elderly.¹⁸ The Medical Ethics Committee of the Erasmus University Medical Centre approved the study, and informed consent was obtained from all subjects. In a random sample of 809 unrelated subjects (the Rotterdam sample), ages 55–65 years, radiographs were scored for the presence of ROA in two knees, two hips,¹⁹ 36 hand joints and three levels of the thoracolumbar spine.^{19,20} All radiographs were scored according to the Kellgren/Lawrence grading system (grades 0–4)¹⁷ by two independent readers, blinded to all other data of the participant. Definite ROA at a particular joint site was defined as a Kellgren/Lawrence score of two or more.¹⁷ In the hands, 36 separate joints were scored comprising eight joint groups: distal interphalangeal joints, the interphalangeal joint of the thumb, the proximal interphalangeal joints, the metacarpophalangeal joints, the first carpo metacarpal joints, the trapezoscaphoideal joints, the radio-navicular joints and the distal radioulnar joints. By definition, ROA of the spine is confined to the apophyseal joints, but these joints could not be assessed on the lateral radiographs of the spine that were available. Instead, we assessed disc degeneration (DD) of the spine, at three levels, that is, thoracic (Th4 to Th12), lumbar (L1–L4 or L5) and lumbosacral (L5–S1 or L5–L6).

We analysed and evaluated the occurrence and the generalised OA status of carriers of novel variants in the population-based sample as a qualitative trait using previously described definitions.¹¹ In brief, subjects with two or more of the following four criteria were considered as affected with generalised ROA: hand ROA in three or more hand joint groups (the right and left hands were considered separately), spinal DD in two or more disc levels, knee ROA in one or two knees and hip ROA in one or two hips. Subjects affected with generalised ROA were compared to the complete Rotterdam sample from which subjects with generalised ROA were excluded. Phenotypic data for assessment of generalised ROA was available for 790 subjects.

Mutation analysis strategy

As the FOA phenotype is likely a Mendelian trait, severe and with an early age of onset, we expect a mutation with a large effect and likely located in a coding region. Moreover, cosegregating haplotypes among families that contributed to the linkage were not identical, indicating either genetic or allelic heterogeneity. Consequently, private mutations in each family may exist. Initially, three affected family members (individual 14 from family 1, individual 10 from family 2 and individual 9 from family 4) were screened for possible mutations by direct forward and reverse sequen-

cing from both ends (Figure 1). To investigate whether detected variants were novel or common SNPs, all variants observed in affected family members were blasted for existence using National Centre of Biotechnology Information (NCBI) SNP blast, build 124 (<http://www.ncbi.nlm.nih.gov/SNP/snpblastByChr.html>). If a novel variant was identified, unaffected family members of these families and family members of remaining families were sequenced and analysed for cosegregation with OA. If the variant cosegregated in at least one family, this variant was genotyped in a random sample of 790 subjects scored for radiographic




Figure 1 Family pedigrees segregating for generalised early-onset OA and chromosome 2q33.3–2q34 loci. Blackened circles and squares indicate affected female and male subjects, respectively. White individuals represent unaffected family members. Crosses indicate recombinations. Shaded individuals indicate individuals with unknown disease status. The black-lined box shows the most likely haplotype (A1), allowing one phenocopy (individual 9) in family 2.

OA to determine the population frequency. The impact of a novel variant involving an amino-acid change was examined using PolyPhen (<http://tux.embl-heidelberg.de/ramensky/index.shtml>) and SIFT (<http://blocks.fhcrc.org/sift/SIFT.html>).²¹ To test the effect on the splicing process, exonic variants were screened for exonic splicing enhancers sequences using <http://exon.cshl.edu/ESE>.²² Conservation was determined using the Multiz Alignments and Conservation track of the UCSC genome browser version 140 (<http://genome.ucsc.edu/>). We applied the nomenclature of den Dunnen and Antonarakis²³ to describe these variants.

Mutation screening

Genomic DNA was isolated from EDTA blood of affected and unaffected family members. Reference sequences corresponding to all coding and 5' and 3' UTR regions of the genes were obtained from the UCSC genome browser assembly May 2004 (<http://genome.ucsc.edu/>) or the Ensembl Genome database v35 (www.ensembl.org), NCBI build 35. Table 1 shows the Genbank numbers. To amplify exons, forward and reverse primer sets (primer sequences upon request) were designed with at least 25 bp flanking intronic sequences using Primer3 (http://www.broad.mit.edu/cgi-bin/primer/primer3_www.cgi) with the conditions described by Vieux *et al.*²⁴ 3'UTR of *NRP2* and exons 1–27 of *PIP5K3* have not been sequenced due to current genome browser updates. PCR amplifications were carried out in a volume of 15 μ l that contained 15 ng genomic DNA, 4.1 pmol of the PCR primers, 1.5 mM MgCl₂, 0.2 mM dNTPs and 0.6 U of *rTaq* polymerase (Amersham Biosciences) or 0.6 U of HotfirePol[®] DNA polymerase and solution S (Solis Biodyne) for GC-rich regions or standard conditions of the GC-rich PCR system (Roche). Reactions were cycled at 94°C for 1 or 15 min for GC-rich regions and then cycled for 35 cycles of 94°C for 30 s, 57°C for 1 min 15 s, 72°C for 30 s, and finally incubated for 6 min at 72°C on B&L primus HT cyclers. PCR products were purified using Multiscreen 96-well plates (Millipore) filled with Sephadex (Amersham biosciences) and quantified on 1.5% agarose gels. PCR products were sequenced for possible mutations using an ABI3730 capillary sequencer with Big Dye chemistry (Applied Biosystems).

Genotyping

Nine novel variants were genotyped in 790 random subjects from the population-based Rotterdam study.¹⁸ All variants were in Hardy–Weinberg equilibrium (HWE). Variants were genotyped using Sequenom homogenous Mass Extend MassARRAY System (Sequenom Inc., San Diego, CA, USA) using standard conditions. Genotypes were analysed using Genotyper version 3.0 software (Sequenom Inc.).

Statistical analysis

HWE was calculated with an exact HWE test for rare alleles implemented in R version 2.3.1, (<http://www.r-project.org/>). A logistic regression model was fitted to measure the strength of association, which is expressed as odds ratios (ORs) with 95% confidence intervals (95% CI) adjusted for age (years), body mass index (BMI in kg/m²) and sex. In these analyses, homo- and heterozygous carriers of the risk allele were pooled. Instead of adjusting *P*-values *a priori* (eg for multiple testing), exact *P*-values are provided in order to let the reader interpret the level of significance. All analyses were performed with SPSS version 11 software (SPSS, Chicago, IL, USA).

Results

Linkage analysis

Results of the genome-wide scan and screening of *PTHR2* and *FZD5* have previously been reported.¹⁶ In brief, significant linkage was observed at 2q33.3–2q34 between markers D2S1384 and D2S2178 implicating a 5 cM interval (4.6 Mb).¹⁶ Recombinant haplotypes were constructed for all families that contributed positively to the linkage. In families 2 and 4, most affected individuals carry identical heterozygous haplotypes resulting in two possible haplotypes explaining the linkage (Figure 1). In family 2, the most likely haplotype 3678 (A1) allows one phenocopy (individual 9) and the second likely haplotype 7658 (A2) allows two phenocopies (subjects 6 and 17). In family 4, the most likely haplotype 5515232 (A1) allows no phenocopies and the second likely haplotype 5144984 (A2) allows one phenocopy (individual 7). Recombinant haplotypes of family 1 and family 2 only were used to determine the minimal restricted region. Cosegregating haplotypes among families were different, indicating either allelic or genetic heterogeneity in these families and assumes the possibilities of private mutations in one or different genes for each family. To detect sequence changes, we initially screened three affected family members from three different families contributing most to the linkage: individual 14 in family 1, individual 10 in family 2 and individual 9 in family 4. When a novel variant was found, segregation analysis of the variant with OA within all family members of the seven families was performed.

Mutation screening of positional candidate genes

Following up these results, we performed extended mutation analysis of the chromosome 2 locus. Using the human genome resources, 18 known RefSeq genes, nine predicted RefSeq genes (four genes with model status and five genes with predicted status in NCBI build 35) have been identified within the linkage area of chromosome 2 as shown in Table 1. Nearby the linkage region, at marker D2S72, the *ICOS-CTLA4-CD28* cluster is located which is implicated in cytokine secretion and T-cell immunity.²⁵

Table 1 Known genes between the markers D2S72 and D2S2178 based on RefSeq, mRNA, TrEMBL and Swiss-Prot prediction using Ensembl genome database v35

Marker	Genbank ID	HUGO ID	Description	No. of exons	
	NM_001037631, NM_005214	CTLA4	Cytotoxic T-lymphocyte protein 4 precursor	3, 4	
	NM_006139	CD28	T-cell-specific surface glycoprotein CD28 precursor	4, 5	
D2S72	NM_012092	ICOS	Inducible T-cell costimulator precursor	5	
D2S1384	NM_057177, NM_205863, NM_152526	ALS2CR19	Amyotrophic lateral sclerosis 2 chromosomal region candidate gene protein 19	22, 23, 23	
	BC009222, NM_201264, NM_018534, NM_201279, NM_003872, NM_201266, NM_017759	NRP2	Neurophilin-2 precursor	5, 16, 16, 16, 17, 17	
		NM_017759	Unknown (NP_060229)	12	
D2S155	NM_005006	NDUFS1	NADH-ubiquinone oxidoreductase 75 kDA subunit	19	
	NM_001959, NM_021121, NM_005279	EEF1B2 GPR1	Elongation factor 1-beta Probable G protein-coupled receptor	6, 7 3	
	XM_371590	XM_371590	Unknown (Q9HCK1)	1	
	XM_496742	XM_496742	Unknown (Q9BZ60)	1	
D2S369	NM_003812	ADAM23	A disintegrin and metalloproteinase 23 preprotein	26	
D2S2358	NM_206892	MDH1B	Malate dehydrogenase 1B (NP_996775)	10	
	NM_014929	NM_014929	Unknown (KIAA0971)	12	
	NM_173077	CPO	Carboxypeptidase O	9	
	NM_003709	KLF7	Krüppel-like factor 7	4	
	NM_004379, NM134442	CREB1	cAMP-response element binding protein	8, 9	
	NM_145280	NM_145280	Hepatocellular carcinoma-associated antigen (NP_660323)	4	
	NM_152523	NM_152523	Hypothetical protein FLJ40432 (NP_689736)	11	
	NM_030804	NM_030804	Unknown (CB031)	1	
	NM_003468	FZD5	Frizzled 5 precursor	2	
	D2S2208	XM_371591	XM_371591	Unknown (Q8VW68)	1
NM_006891		CRYGD	Gamma crystallin D	3	
NM_020989		CRYGC	Gamma crystallin C	3	
NM_005210		CRYGB	Gamma crystallin B	3	
NM_014617		CRYGA	Gamma crystallin A	3	
XM_371592		XM_371592	Similar to RIKEN cDNA D630023F18	9	
NM_005896		IDH1	Isocitrate dehydrogenase 1	10	
NM_152671, NM_015040		PIP5K3	FYVE finger-containing phosphoinositide	10, 42	
D2S2178		NM_005048	PTHR2	Parathyroid hormone receptor precursor	13

FRZB is a very consistent locus associated with *hip*^{10,12} and generalised OA,¹¹ which is localised at 2q32, slightly outside our linkage region. To exclude the possibility that a *FRZB* mutation influences the early-onset generalised OA in any of our families, we also included this gene. The entire coding region, splice sites, and 5' and 3' untranslated

regions of *FRZB*, *CTLA4*, *CD28*, *ICOS*, *NRP2*, *NM_017759*, *NDUFS1*, *EEF1B2*, *GPR1*, *XM_371590*, *ADAM23*, *MDH1B*, *CPO*, *KLF7*, *CREB1*, *NM_030804*, *FZD5*, *IDH1*, *PIP5K3* and *PTHR2* were sequenced comprising 17 RefSeq genes and three predicted genes. Results of the screening of *PTHR2* and *FZD5* have previously been reported.¹⁶ If the

considered variant appeared novel in the current dbSNP database (build 124) and cosegregated with OA in at least one affected family, it was evaluated according to the criteria previously mentioned.

Evaluation of novel variants

The initial screening indicated 26 novel variants (17 SNPs and nine insertion/deletion polymorphisms). From these 26 variants, only nine promising variants cosegregated with OA within one or more families as illustrated in Table 2. Three of these variants were found in coding regions and involved an amino-acid change: *XM_371590* R2133S, *IDH1* Y183C and *PTHR2* A225S. Six variants were located in UTR regions (*PIP5K3* c.8429T>A, *PIP5K3* c.8434insC and *NRP2* c.941A>C) or in vicinity of exon/intron boundaries (*NRP2* c.1938-21T>C, *ADAM23* c.2065 + 24C>T and *IDH1* c.933-28C>T). To estimate the allele frequencies, these nine cosegregating variants were genotyped in a random population sample, screened for radiographic signs in hand, hip, spine and knee.

Using PolyPhen, SIFT and ESE finder analysis to predict possible functional effects of these variants, two variants emerged as potential mutations: *XM_371590* R2133S and *IDH1* Y183C (Table 2). In addition, three variants (*NRP2* c.941A>C, *PIP5K3* c.8429T>A and *PIP5K3* c.8434insC) were conserved across other species and might be of functional importance.

The predicted *XM_371590* gene probably belongs, as predicted in Unigene, to the fibronectin type III and M protein repeat family in *C. elegans*. Fibronectin is a component of the ECM and *XM_371590* may therefore be an excellent candidate gene. The G/T nucleotide change in the third exon of *XM_371590* (Q9HCK1) results in disruption of exonic splicer enhancer motifs which serves as binding site for serine/arginine protein 40 and 55 and might be, therefore, a functional variant. However, because this gene is a predicted gene, little is known about other possible predicted functional effects on the protein. The novel variant *XM_371590* R2133S cosegregated in families 4 and 7 with OA and showed a rare population frequency of 0.01 corresponding to nine carriers of 763 genotyped (Table 3). In the Rotterdam sample, we did not observe a significant association of this variant with generalised ROA. It is unlikely that this variant is a causal mutation.

Isocitrate dehydrogenase 1 encodes a cytoplasmic enzyme which catalyses the oxidative decarboxylation of isocitrate to 2-oxoglutarate and has a significant role in cytoplasmic NADPH production.²⁶ In *IDH1*, two variants (Y183C and c.933-28C>T) cosegregated with the OA phenotype. *IDH1* Y183C cosegregated in affected family members in family 2 (A2, Figure 1). This variant was located in exon 6 encoding the isocitrate/isopropylmalate dehydrogenase domain (PF00180) of *IDH1*, predicted to be probably damaging for the protein structure/function by SIFT and PolyPhen, and highly conserved across all species

Table 2 Possible mutations segregating in FOA families

Gene	Gene location	DNA nt change ^a	Amino-acid change	Sequence conservation ^b	Splicing ^c	PolyPhen ^d	SIFT ^e	Segregation family ^f
<i>NRP2</i>	3'UTR ^g	c.941A>C		No				F4:A1
<i>NRP2</i>	Intron 7 ^h	c.1938-21T>C		No	Possible			F2:A1, F4:A2, F1:A1
<i>XM_371590</i>	Exon 1	c.6368G>T	R2133S	No	Yes	Benign (1.35) ⁱ	Tolerated (0.00) ⁱ	F4:A1, F7:A1
<i>ADAM23</i>	Intron 20	c.2065+24C>T		No	Possible			F2:A2
<i>IDH1</i>	Exon 6	c.782A>G	Y183C	Yes	No	Damaging (2.89)	Not tolerated (0.00)	F2:A2
<i>IDH1</i>	Intron 6	c.933-28C>T		No	Possible			F2:A1, F4:A2
<i>PIP5K3</i>	3'UTR	c.8429T>A		Yes				F4:A2
<i>PIP5K3</i>	3'UTR	c.8434insC		No				F4:A2
<i>PTHR2</i>	Exon 6	c.786G>T ^j	A225S	No	No	Benign (0.12)	Tolerated (0.77)	F4:A2

^aNumbers are based on positions in BC009222 (gi:33874364), NM_201267 (gi:41872566), *XM_371590* (gi:42656560), NM_003812 (gi:73765550), NM_005896 (gi:28178824), NM_015040 (gi:50881947) and NM_005048 (gi:39995097).

^bSequence conservation based on vertebrate Multiz Alignment and Conservation of 17 species (UCSC Genome browser).

^cSplicing effects in exons have been predicted by ESE finder.

^dPolyPhen prediction PSIC score difference.

^eSIFT prediction with normalized probability.

^fA1 represents the most likely haplotype and A2 the second likely affected haplotype.

^gThis variant is located in one of the six transcripts (BC009222, gi:33874364).

^hThis variant is located in six of the seven transcripts (NM_201267 (gi:41872566), NM_003872 (gi:41872532), NM_201279 (gi:41872571), NM_018534 (gi:41872543), NM_201266 (gi:41872561) and NM_201264 (gi:41872556)).

ⁱPoor predictions due to little information.

^jThis variant has been described in Meulenbelt *et al.*¹⁶

Table 3 Frequencies of novel segregating variants in population-based sample scored for generalised ROA (GOA)

Variant	Total ^a (n = 790)	No GOA ^b (n = 659)	GOA ^b (n = 131)	P ^c
<i>NRP2</i> c.941A>C	0.03 (743)	0.03 (601/17)	0.02 (123/2)	0.44
<i>NRP2</i> c.1938-21T>C ^d	0.07 (741)	0.07 (574/40)	0.12 (112/15)	0.03
<i>XM_371590</i> c.6368G>T	0.01 (763)	0.01 (630/7)	0.02 (124/2)	0.47
<i>ADAM23</i> c.2065+24C>T	0.04 (741)	0.04 (591/22)	0.03 (124/4)	0.79
<i>IDH1</i> c.782A>G	0.02 (767)	0.01 (631/9)	0.04 (122/5)	0.10
<i>IDH1</i> c.933-28C>T	0.04 (773)	0.04 (622/23)	0.04 (123/5)	0.94
<i>PIP5K3</i> c.8429T>A ^d	0.04 (756)	0.04 (603/25)	0.04 (123/5)	0.83
<i>PIP5K3</i> c.8434insC ^d	0.04 (734)	0.04 (592/24)	0.04 (113/5)	0.96

^aFrequency (total genotyped subjects).

^bFrequency (*n* carriers of two common alleles/*n* carriers of one or two rare alleles).

^cP-values adjusted for age, BMI and sex.

^dHeterozygous and homozygous carriers were pooled (one, one and two homozygous carriers for *NRP2* c.1938-21T>C, *PIP5K3* c.8429T>A and *PIP5K3* c.8434insC, respectively).

investigated. Based on these results, this variant could be functional for the onset of generalised OA. In the Rotterdam sample, we observed 14 carriers out of 767 genotyped corresponding to a frequency of 0.02. In addition, carriers of this variant conferred an OR, adjusted for age, BMI and sex of 2.8 (95% CI, 0.82–9.7, $P=0.10$) to have generalised ROA, as shown in Table 3.

Another variant in this gene, *IDH1* c.933–28C>T, was identified in families 2 and 4, near the intron/exon boundary of exon 7. This variant was not conserved across other species, and was not associated with generalised ROA in the Rotterdam sample (frequency 0.04).

Neuropilin 2 (*NRP2*) is an interesting gene because it encodes for the co-receptor of vascular endothelial growth factor₁₆₅ (VEGF₁₆₅), which is an essential factor for endochondral ossification.²⁷ Furthermore, VEGF and its receptors are expressed in OA cartilage and VEGF stimulates production of ECM-degrading matrix metalloproteinases (MMPs).^{28,29} In the *NRP2* gene, two novel variants were found: c.941A>C and c.1938-21T>C. In family 4, *NRP2* c.941A>C was identified in a residue with a low conservation score. This variant showed a frequency of 0.03 in the random population and no significant association with generalised ROA was observed. The second *NRP2* variant, c.1938-21T>C, was not conserved and cosegregated in three families (1, 2 and 4) and was more frequent in the population (0.07). Carriers of at least one risk allele of the *NRP2* c.1938-21T>C variant conferred an increased risk of 2.1 (95% CI, 1.1–4.1, $P=0.032$), adjusted for age, sex, BMI, to have generalised ROA (Table 3).

Phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, type III catalyses the phosphorylation of phosphatidylinositol-4-phosphate and has a role in endosome-related membrane trafficking.³⁰ We found two novel variants (*PIP5K3* c.8429T>A and *PIP5K3* c.8434insC) in the 3'UTR region of *PIP5K3* in family 4. *PIP5K3* c.8429T>A involved a highly conserved residue. *PIP5K3* c.8434insC was not conserved. In the Rotterdam sample, we observed that *PIP5K3* c.8429T>A and *PIP5K3* c.8434insC showed a

population frequency of 0.04 and were in complete LD ($D'=1$, $r^2=1$). In the Rotterdam sample, no significant associations of these variants with generalised ROA were observed excluding a possible pathogenic role in relation to the onset of FOA. Even though *PIP5K3* c.8429T>A occurred in a conserved residue, it is likely that these variants are neutral polymorphisms.

Finally, we also examined whether some novel variants were inherited together in different families to identify a possible LD pattern or genetic interaction resulting in a high LOD score linked to OA. As shown in Table 2, only two variants, *NRP2* c.1938-21T>C and *IDH1* c.933-28C>T, occurred together on haplotype A1 in family 2 and on haplotype A2 in family 4. In the random population, this inheritance pattern was observed only once in 754 genotyped subjects (0.0013). This individual had spinal DD at three disc levels that has a prevalence of 0.04 in the random population.

Discussion

Upon screening 20 genes localised within or near the area of linkage in three families that contributed most to the linkage, we identified nine novel variants cosegregating with OA. We evaluated the significance of the novel variants by prediction of pathogenicity using *in silico* functional analysis and by establishing the frequency in the random population. The *IDH1* Y183C variant cosegregated on haplotype A2 with the OA phenotype in family 2 was predicted to be probably damaging for the protein structure/function and concerned a highly conserved residue. Among carriers of this variant in the general population (frequency 0.02), the risk of generalised ROA was 2.8 (95% CI, 0.82–9.7, $P=0.10$). Given these results and the likelihood of allelic heterogeneity among these families in combination with the significant LOD score in family 2 alone, this variant may contribute to the FOA susceptibility in family 2. *IDH1* supplies NADPH for antioxidant systems, suggesting a regulatory role in cellular

defense against oxidative stress and in senescence.³¹ Little is known about a possible role of *IDH1* in cartilage but we speculate that increased oxidative stress could make chondrocytes more susceptible to cell death which might contribute to the onset of OA.

A second variant, *NRP2* c.1938–21T>C, emerged from our mutation analysis which cosegregated in three families (1, 2 and 4) contributing most to the linkage. Carriers of this variant conferred an increased risk of 2.1 (95% CI, 1.1–4.1, $P=0.032$) to have generalised ROA.

NRP2 acts as a co-receptor of VEGF₁₆₅, which is produced from hypertrophic chondrocytes and is also expressed in OA cartilage.^{28,32} VEGF is an essential coordinator of growth plate morphogenesis and triggers cartilage remodelling.²⁷ VEGF may contribute to OA cartilage destruction through stimulation of MMPs.^{28,29,33}

Given the high frequency (0.02 and 0.07) and the low effect sizes for generalised ROA in the random population, both variants are unlikely to represent a causative, highly penetrant mutation. Mendelian traits are often oligogenic and/or have modifier genes explaining phenotypic variability.³⁴ Although our linkage signal may not be explained by these variants, a possible modulating role for these variants or genetic interaction with other causal variants at this or other loci cannot be excluded.

The *NRP2* c.1938–21T>C occurred together with *IDH1* c.933–28C>T on haplotype A1 in family 2 and on haplotype A2 in family 4. This haplotype is extremely rare in the random population (0.0013). At this point, we conclude that possibly a causal variant in the LD pattern driven by both variants may have contribution to OA in families 2 and 4. The pathogenic potential of these variants and the role of this haplotype in the OA phenotype should be confirmed further in other populations with advanced OA or supported by functional assays.

The reduced penetrance among carriers in the Rotterdam study may be explained by the low frequency of the carriers, the absence of a clinical OA assessment and the relatively high frequency of generalised ROA above 55 years (0.17), which can result in reduced power of the statistical test, misclassification and spurious associations. We also analysed the presence of ROA among carriers in the random population as quantitative trait using a sum score of the number of affected joints¹⁶ which revealed similar findings (data not shown).

There is a possibility that the family members could be affected with generalised ROA by chance alone although the phenotype is more severe (clinical OA before age 50 years). In family 2 and family 4, we observed two possible haplotypes segregating with the disease allowing one or two phenocopies, suggesting that these individuals could be sporadic patients. Both haplotypes (A1 and A2) confined the linkage area. Consistent with an age-related disorder, we were not able to perform further segregation analysis

because first-degree relatives died or are too young to reveal symptoms of the disease.

We prioritised genes for sequencing based on the function known in the literature and human genome resources. Obviously, unselected genes could carry an OA causing allele and will be screened for mutations in the future. In addition, we selected families that contribute most to the linkage for the initial mutation survey. Apparently, remaining four families could harbour causal variants in one of the screened genes. Alternatively, it is possible that affected family members may have a noncoding regulatory mutation in promoter or intron or a heterozygous deletion of one or more of the exons in one of the screened genes that has not yet been detected in our study.

In addition, predictions on the basis of computational algorithms as PolyPhen, SIFT and ESE finder are difficult to interpret. Furthermore, even variants that are associated with disease may be in linkage disequilibrium with the true causal variant or are rare polymorphisms.

Although we were able to identify nine novel variants cosegregating with the FOA phenotype by our extended mutation analysis, we may found no robust evidence for a major disease gene responsible for the observed linkage to the FOA phenotype. Our results, however, might indicate a possible modulating role for variants in or near *NRP2* and *IDH1*. Further mutation analysis of the linkage area on chromosome 2q33.3–2q34 and confirmation of the most promising variants in other populations with advanced OA is needed.

Acknowledgements

We thank Dr JK van der Korst (J van Breemen Institute, Amsterdam), Dr PJJM Rompa (Gooi Noord, Blaricum), Professor Dr JJ Rasker (Med. Spectrum Twente, Enschede), W Hissink-Muller, AJM Schoffelen, PJM Konings, J de Waal Malefijt (Maria Hospital, Tilburg), Professor Dr RGT Geesink and Professor AJ vd Linden (Academic Hospital, Maastricht), Dr MC Kraan and Dr N Riyazi (Leiden Medical Hospital, Leiden), Dr EJ van Langelaan (Rijnland Hospital, Leiderdorp), Dr K Ronday, (Leijenburg Hospital The Hague) and Dr H Knoblauch (Universitätsklinikum Charite, Berlin) for providing us with the radiographs and medical histories of their patients. This work was supported by the Leiden University Medical Centre, the Dutch Arthritis Association (RF 001-301), the Centre of Medical System Biology and the Netherlands Organization of Scientific Research (MW 904-61-095).

References

- 1 Spector TD, MacGregor AJ: Risk factors for osteoarthritis: genetics. *Osteoarthritis Cartilage* 2004; 12 (Suppl A): S39–S44.
- 2 Loughlin J: Genetic epidemiology of primary osteoarthritis. *Curr Opin Rheumatol* 2001; 13: 111–116.
- 3 Ingvarsson T, Stefansson SE, Gulcher JR *et al*: A large Icelandic family with early osteoarthritis of the hip associated with a susceptibility locus on chromosome 16p. *Arthritis Rheum* 2001; 44: 2548–2555.

- 4 Jakkula E, Melkonieni M, Kiviranta I *et al*: The role of sequence variations within the genes encoding collagen II, IX and XI in non-syndromic, early-onset osteoarthritis. *Osteoarthr Cartilage* 2005; **13**: 497–507.
- 5 Meulenbelt I, Bijkerk C, Breedveld FC, Slagboom PE: Genetic linkage analysis of 14 candidate gene loci in a family with autosomal dominant osteoarthritis without dysplasia. *J Med Genet* 1997; **34**: 1024–1027.
- 6 Reginato AM, Olsen BR: The role of structural genes in the pathogenesis of osteoarthritic disorders. *Arthritis Res* 2002; **4**: 337–345.
- 7 Ikeda T, Mabuchi A, Fukuda A *et al*: Association analysis of single nucleotide polymorphisms in cartilage-specific collagen genes with knee and hip osteoarthritis in the Japanese population. *J Bone Miner Res* 2002; **17**: 1290–1296.
- 8 Min JL, Meulenbelt I, Riyazi N *et al*: Association of matrilin-3 polymorphisms with spinal disc degeneration and with osteoarthritis of the CMC1 joint of the hand. *Ann Rheum Dis* 2006; **65**: 1060–1066.
- 9 Stefansson SE, Jonsson H, Ingvarsson T *et al*: Genomewide scan for hand osteoarthritis: a novel mutation in matrilin-3. *Am J Hum Genet* 2003; **72**: 1448–1459.
- 10 Loughlin J, Dowling B, Chapman K *et al*: Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. *Proc Natl Acad Sci USA* 2004; **101**: 9757–9762.
- 11 Min JL, Meulenbelt I, Riyazi N *et al*: Association of the frizzled-related protein gene with symptomatic osteoarthritis at multiple sites. *Arthritis Rheum* 2005; **52**: 1077–1080.
- 12 Lane NE, Lian K, Nevitt MC *et al*: Frizzled-related protein variants are risk factors for hip osteoarthritis. *Arthritis Rheum* 2006; **54**: 1246–1254.
- 13 Forster T, Chapman K, Loughlin J: Common variants within the interleukin 4 receptor alpha gene (IL4R) are associated with susceptibility to osteoarthritis. *Hum Genet* 2004; **114**: 391–395.
- 14 Kizawa H, Kou I, Iida A *et al*: An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. *Nat Genet* 2005; **37**: 138–144.
- 15 Mototani H, Mabuchi A, Saito S *et al*: A functional single nucleotide polymorphism in the core promoter region of CALM1 is associated with hip osteoarthritis in Japanese. *Hum Mol Genet* 2005; **14**: 1009–1017.
- 16 Meulenbelt I, Min JL, Van Duijn CM *et al*: Strong linkage on 2q33.3 to familial early onset generalised osteoarthritis and a consideration of two candidate genes. *Eur J Hum Genet* 2006; **14**: 1280–1287.
- 17 Kellgren JH, Jeffrey MR, Ball J: *The Epidemiology of Chronic Rheumatism. Volume II: Atlas of Standard Radiographs of Arthritis*. Oxford: Blackwell Scientific Publications, 1963.
- 18 Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA: Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. *Eur J Epidemiol* 1991; **7**: 403–422.
- 19 Odding E, Valkenburg HA, Stam HJ, Hofman A: Determinants of locomotor disability in people aged 55 years and over: the Rotterdam Study. *Eur J Epidemiol* 2001; **17**: 1033–1041.
- 20 Bijkerk C, Houwing-Duistermaat JJ, Valkenburg HA *et al*: Heritabilities of radiologic osteoarthritis in peripheral joints and of disc degeneration of the spine. *Arthritis Rheum* 1999; **42**: 1729–1735.
- 21 Ng PC, Henikoff S: Accounting for human polymorphisms predicted to affect protein function. *Genome Res* 2002; **12**: 436–446.
- 22 Wang J, Smith PJ, Krainer AR, Zhang MQ: Distribution of SR protein exonic splicing enhancer motifs in human protein-coding genes. *Nucleic Acids Res* 2005; **33**: 5053–5062.
- 23 den Dunnen JT, Antonarakis SE: Nomenclature for the description of human sequence variations. *Hum Genet* 2001; **109**: 121–124.
- 24 Vieux EF, Kwok PY, Miller RD: Primer design for PCR and sequencing in high-throughput analysis of SNPs. *Biotechniques* 2002; (Suppl): 28–30, 32.
- 25 Rudd CE, Schneider H: Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. *Nat Rev Immunol* 2003; **3**: 544–556.
- 26 Geisbrecht BV, Gould SJ: The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. *J Biol Chem* 1999; **274**: 30527–30533.
- 27 Gerber HP, Vu TH, Ryan AM *et al*: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. *Nat Med* 1999; **5**: 623–628.
- 28 Enomoto H, Inoki I, Komiya K *et al*: Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. *Am J Pathol* 2003; **162**: 171–181.
- 29 Pufe T, Harde V, Petersen W *et al*: Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. *J Pathol* 2004; **202**: 367–374.
- 30 Sbrissa D, Ikononov OC, Shisheva A: Phosphatidylinositol 3-phosphate-interacting domains in PIKfyve. Binding specificity and role in PIKfyve. Endomembrane localization. *J Biol Chem* 2002; **277**: 6073–6079.
- 31 Kil IS, Huh TL, Lee YS, Lee YM, Park JW: Regulation of replicative senescence by NADP(+)-dependent isocitrate dehydrogenase. *Free Radic Biol Med* 2006; **40**: 110–119.
- 32 Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G: Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. *J Biol Chem* 2000; **275**: 18040–18045.
- 33 Tanaka E, Aoyama J, Miyauchi M *et al*: Vascular endothelial growth factor plays an important autocrine/paracrine role in the progression of osteoarthritis. *Histochem Cell Biol* 2005; **123**: 275–281.
- 34 Antonarakis SE, Beckmann JS: Mendelian disorders deserve more attention. *Nat Rev Genet* 2006; **7**: 277–282.